Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 18/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535715 | 0.89 | SSTR5 (0.44) | SSTR5SLC6A4SLC6A3 | |
| SCHEMBL17535520 | 0.88 | SSTR5 (0.45) | SSTR5SLC6A4SLC6A3KCNH2 | |
| SCHEMBL17535388 | 0.87 | SLC6A4 (0.40) | SSTR5SLC6A4SLC6A3KCNH2 | |
| SCHEMBL17535828 | 0.87 | SLC6A4 (0.40) | SSTR5SLC6A4SLC6A3KCNH2 | |
| SCHEMBL17535469 | 0.87 | SSTR5 (0.37) | SSTR5SLC6A3KCNH2 | |
| SCHEMBL16616292 | 0.85 | SLC6A3 (0.40) | SSTR5SLC6A4SLC6A3 | |
| SCHEMBL17535817 | 0.83 | SLC6A3 (0.44) | SSTR5SLC6A4SLC6A3 | |
| SCHEMBL16056254 | 0.79 | TDP1 (0.35) | SLC6A3 | |
| SCHEMBL17535719 | 0.79 | SSTR5 (0.44) | SSTR5KCNH2 | |
| SCHEMBL23459274 | 0.77 | SLC6A3 (0.46) | SSTR5SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | SSTR5 1/4885SLC6A4 88/4885SLC6A3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.